We develop treatment methods with unique properties in the therapeutic fields of migraine, pain related to cancer, opioid overdose and anaphylactic shock.
Download the Company Description.
Year end report, 2019
Today, Klaria announces that the company will re-acquire all global rights to Naloxone Alginate Film (KL-00514) from Purdue Pharma (Canada). The continued...
Klaria Pharma Holding Quarterly Report Q1 2019
We are using cookies to optimize your browsing experience. By continuing your browsing you consent to such use.